Caprion Pharmaceuticals and Wyeth Announce Biomarker Research Collaboration
July 16, 2003, Montreal, Canada - Caprion Pharmaceuticals and Wyeth (NYSE: WYE) today announced a research collaboration to identify biomarkers of the effects of Wyeth's pharmaceutical compounds using Caprion's CellCartaTM proteomics discovery platform.
Under the terms of the agreement, Caprion will profile plasma changes in a preclinical model of inflammation after administration of Wyeth proprietary compounds. The companies expect to uncover novel biological insights that will augment the understanding of the mechanisms of action of these compounds and aid in the optimization of these and other promising therapeutics.
"We are pleased to begin this biomarker relationship with Wyeth," said Dr. Daniel Chelsky, Chief Scientific Officer of Caprion Pharmaceuticals. "Together with other collaborations that are currently underway at Caprion, this study reflects how Caprion's biomarker discovery capability addresses a key biopharmaceutical need and reinforces the value of the biological data that we generate."
Caprion's proprietary proteomics technology comprehensively and quantitatively profiles the proteins contained in tissues and blood. In September 2002, Caprion announced a collaboration employing this technology with IDEC Pharmaceuticals (Nasdaq: IDPH) for the identification of colorectal cancer tumor antigen targets.
Caprion is a leader in proteomics-based drug discovery, enabling innovative approaches for diagnosing and treating disease. Caprion's proprietary technology platform comprehensively profiles human tissues and serum by integrating proprietary organelle isolation and sample decomplexification, quantitative mass spectrometry, and advanced bioinformatics. The Company's mission is to leverage these distinctive capabilities through R&D partnerships to generate the most comprehensive profiles of health and disease proteomes under study. Its drug discovery programs are focused on Tumor Antigen Discovery, Biomarker Discovery, and Compound Mechanism of Action elucidation. The Company also has partnered products for Mad Cow Disease and variant Creutzfeldt-Jacob Disease diagnostics, in development with IDEXX Laboratories and Ortho-Clinical Diagnostics. For more on Caprion, see www.caprion.com.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, and commercialization, economic conditions including interest and currency exchange rate fluctuations, the impact of competitive or generic products, product liability and other types of lawsuits, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties, including those detailed from time to time in Wyeth's periodic reports, including quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Caprion Pharmaceuticals Inc.
Chief Financial Officer